United States Patent 4,375,547: Scope, Claims, and Patent Landscape
United States Patent 4,375,547 is directed to a single claimed chemical entity identified by its full structural name: N-methyl-N'-([2-(dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine. The claim as provided is a Markush-style closed-form “compound” claim in which scope is defined by the exact named molecule, not by functional or genus variables.
What does the lone claim cover?
Claim 1 (as provided):
“A compound said compound being N-methyl-N'-([2-(dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine.”
This is the core scope determinant: infringement turns on whether the accused compound is that specific chemical structure (or a legally equivalent structure, depending on claim construction and doctrine of equivalents, where applicable). There is no stated breadth in your excerpt for:
- substituted variants, analogs, salts, solvates, or prodrugs
- alternative linkers (e.g., different thiazole substitution patterns)
- alternative nitro/enediamine substitution patterns
- alternative “N-methyl” or dimethylaminomethyl motifs
With only the chemical name, the claim reads as single-identity rather than a broad genus.
How broad is Claim 1 in practice?
Claim coverage is best analyzed as a three-part test: (1) identity, (2) structure-defining fragments, (3) absence of permissive language.
1) Identity test
The claim is written as “a compound… being [one chemical name].” That is a closed identity claim. It does not say “comprising,” “selected from,” or “wherein,” and it does not include alternatives. If the accused compound differs at any atom that changes the named structure, it falls outside literal scope.
2) Structure-defining fragments (what must match)
Even without drawing the structure, the name encodes fixed substructures:
- Nitro-enediamine core: “2-nitro-1,1-ethenediamine”
- Thiazole motif: “4-thiazolyl” with a “2-(dimethylaminomethyl)” substituent
- S-thioether linkage: “methylthio” connecting the thiazolyl-methylthio fragment to the ethyl diamine nitrogen substituent chain
- N-methyl substitution: “N-methyl-N'-(...)” fixes the N-substitution pattern
- Ethyl connector: “ethyl” appears in the chain between the N' substitution and the diamine core
Any competitor compound that keeps only one or two motifs (for example, same thiazole and nitro-enediamine but different N-substitution or different tethering group) is not within this claim as written.
3) No claim features that expand scope
In your provided claim text, the following are not present:
- “pharmaceutically acceptable salts”
- “hydrates, solvates”
- “prodrugs”
- “treatment of” or “use for” language that can broaden interpretation via method-of-use doctrine
If those concepts exist in the full patent text, they are not captured in the single claim excerpt you supplied.
What is the likely technology scope implied by the chemical name?
The claim identifies a molecule that contains a nitro-enediamine plus a thiazole with dimethylaminomethyl substitution. That combination strongly suggests an antimicrobial or antiparasitic small molecule class, but this is a scope implication, not claim scope itself.
From a patent-landscape perspective, chemical-name-defined claims typically create:
- direct product barriers for any exact-structure generic entrant
- follow-on freedom-to-operate (FTO) opportunities for analog design that changes the tethering or N-substitution while preserving the general pharmacophore
What does the claim structure say about infringement posture?
Because Claim 1 is an identity compound claim, an enforcement strategy usually relies on:
- comparison of the accused compound to the exact named structure
- expert structural comparison using spectroscopic/analytical data and chemical structure conversion
For generic challenge scenarios, the common litigation pivot is:
- whether the generic product is truly the same compound (identity)
- whether a salt/formulation changes the “compound” being practiced (if the patent has salt language in the full spec/claims)
Your claim excerpt contains no explicit salt language, so the strictest reading is identity to the named compound.
What is the likely patent landscape position of US 4,375,547?
Without the remaining claims/spec and without bibliographic data beyond the number, the landscape analysis can only be anchored to the claim type and uniqueness.
Landscape buckets typically affected by a single-compound claim
- Exact-structure generics: Directly target the same molecule. If a generic is that same compound, it is exposed to Claim 1 infringement risk (subject to validity and claim construction).
- Analog developers: Modify one fixed fragment to avoid literal identity. They may still face risk under:
- other claims (if the full patent includes Markush/genus claims)
- continuation patents or related filings by the same assignee
- enforceability against “equivalents” depending on jurisdiction and case law
- Formulation/salt entrants: If the patent family includes broader claims on salts/solvates or dosage forms, those entrants face additional barriers. Your excerpt does not indicate this.
Most common follow-on patterns
For chemical inventions like this, the practical landscape often includes:
- later patents by the same assignee on salts, polymorphs, stereochemical variants, prodrugs, or improved processes
- competitor patents on related scaffolds that keep the thiazole and nitro-enediamine motifs but alter the side-chain substitution or linkage
The key point: Claim 1 as written gives no built-in breadth for those follow-ons unless other claims exist in US 4,375,547.
How can this claim be mapped into a defensible FTO decision rule?
Given only the provided Claim 1, the FTO rule for a chemical program is straightforward:
Direct infringement trigger
An accused compound is within scope if it is N-methyl-N'-([2-(dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine.
Avoidance design targets (literal non-infringement)
A design-around strategy must change at least one atom-level feature represented by the claim name, especially:
- the “N-methyl” substitution on N
- the “N'-(...ethyl...)” tether length or attachment point
- the “methylthio” linkage pattern
- the “2-(dimethylaminomethyl)-4-thiazolyl” substitution pattern
- the “2-nitro-1,1-ethenediamine” nitro/enediamine positional framework
If the marketed compound matches the entire name exactly, design changes must be comprehensive.
What specific information is missing for a full landscape (and why the claim still constrains scope)?
A complete landscape typically requires:
- inventor/assignee and filing dates (for family mapping)
- specification details (process, intermediates, salts, polymorphs)
- all claims (to confirm whether there are genus or subgenus claims beyond Claim 1)
- citations/forward citations to identify later publications that may be controlling
Your excerpt provides only Claim 1, which is enough to determine the exact-identity nature of the protection in that claim. That is the dominant driver for a chemical compound claim: it defines the barrier to only that single structure, absent other claims.
Key Takeaways
- US 4,375,547 Claim 1 is an identity compound claim that covers only N-methyl-N'-([2-(dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine, as written.
- The scope is not expressed as a genus (no “wherein” variables, no Markush alternatives in the provided claim text).
- Practical enforcement and design-around focus on atom-level matching of the named core motifs: nitro-enediamine, 4-thiazolyl, dimethylaminomethyl substituent, methylthio linkage, and N-methyl/N' ethyl tether.
- For FTO, the decision rule is structural identity to the named compound unless other claims in the patent (not provided) broaden coverage.
FAQs
-
Is Claim 1 broad or narrow?
Narrow. It is a single-compound identity claim defined by a full chemical name.
-
Does Claim 1 cover salts or solvates?
The provided claim text does not state salt or solvate coverage, so scope in this excerpt is limited to the named compound form.
-
Would analogs avoid infringement automatically?
Yes for literal infringement under this claim, so long as the analog differs in the structural elements encoded by the exact name.
-
What is the main litigation issue for a competitor?
Structural identity: whether the accused compound is the same molecule as specified in Claim 1.
-
Can other claims in the same patent broaden scope?
Yes, but they are not provided here. The landscape conclusions based on the excerpt must be treated as specific to Claim 1 only.
References
[1] United States Patent 4,375,547, Claim 1 (provided).
